The Prostate

Division of Medical Quantum Science, Department of Health Sciences, Kyushu University, Fukuoka, Japan Division of Medical Quantum Science, Department of Health Sciences, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Department of Radiology, Saga University Hospital, Saga University, Saga, Japan

[1]  V. Costa,et al.  The Multifaceted Role of Annexin A1 in Viral Infections , 2023, Cells.

[2]  K. Harada,et al.  Diagnostic and therapeutic value of pelvic lymph node dissection in the fossa of Marcille in patients with clinically localized high‐risk prostate cancer: Histopathological and molecular analyses , 2020, The Prostate.

[3]  K. Akakura,et al.  Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxel. , 2019, The Prostate.

[4]  O. Ogawa,et al.  Docetaxel‐based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration‐resistant prostate cancer: Long‐term outcomes , 2019, International journal of urology : official journal of the Japanese Urological Association.

[5]  T. Tsuzuki,et al.  The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance , 2019, The Prostate.

[6]  Onno J de Boer,et al.  Deep learning for automatic Gleason pattern classification for grade group determination of prostate biopsies , 2019, Virchows Archiv.

[7]  F. Migliorini,et al.  Lymph Nodes Invasion of Marcille’s Fossa Associates with High Metastatic Load in Prostate Cancer Patients Undergoing Extended Pelvic Lymph Node Dissection: The Role of “Marcillectomy” , 2019, Urologia Internationalis.

[8]  K. Akakura,et al.  Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer , 2019, Journal of clinical medicine.

[9]  Septimiu E. Salcudean,et al.  Comparison of Artificial Intelligence Techniques to Evaluate Performance of a Classifier for Automatic Grading of Prostate Cancer From Digitized Histopathologic Images , 2019, JAMA network open.

[10]  M. Shiota,et al.  Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer. , 2019, Urologic oncology.

[11]  R. Ghavamian,et al.  Current controversies on the role of lymphadenectomy for prostate cancer. , 2019, Urologic oncology.

[12]  Y. Bao,et al.  The Prognostic Value of the Proportion and Architectural Patterns of Intraductal Carcinoma of the Prostate in Patients with De Novo Metastatic Prostate Cancer , 2019, The Journal of urology.

[13]  Gang Wang,et al.  Automatic grading of prostate cancer in digitized histopathology images: Learning from multiple experts , 2018, Medical Image Anal..

[14]  W. Zwart,et al.  Molecular underpinnings of enzalutamide resistance. , 2018, Endocrine-related cancer.

[15]  H. G. van der Poel,et al.  Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond , 2018, Endocrine-related cancer.

[16]  Harold Evelyn Taitt.  Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location , 2018, American journal of men's health.

[17]  N. Nonomura,et al.  Role of Androgen Receptor in Prostate Cancer: A Review , 2018, The world journal of men's health.

[18]  T. Uchiumi,et al.  Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants , 2018, Cancer science.

[19]  H. Akaza,et al.  Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community‐based multi‐institutional database across Japan using propensity score matching , 2018, Cancer medicine.

[20]  M. Shiota,et al.  Serum testosterone before and during androgen‐deprivation therapy, and prognosis between cigarette smokers and nonsmokers with metastatic prostate cancer , 2018, Andrologia.

[21]  Liying Zhang,et al.  A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy , 2018, The Journal of urology.

[22]  P. Kantoff,et al.  The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer , 2018, The Journal of urology.

[23]  A. Mes-Masson,et al.  The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer‐specific survival , 2018, The Prostate.

[24]  F. Saad,et al.  Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer , 2018, The New England journal of medicine.

[25]  Xiang Li,et al.  Novel nomograms for castration‐resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancer , 2018, BJU international.

[26]  F. Burkhard,et al.  More extended lymph node dissection template at radical prostatectomy detects metastases in the common iliac region and in the fossa of Marcille , 2018, BJU international.

[27]  P. Kantoff,et al.  Current treatment strategies for advanced prostate cancer , 2018, International journal of urology : official journal of the Japanese Urological Association.

[28]  Yuhong Yuan,et al.  The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: A systematic review , 2018 .

[29]  T. Schuster,et al.  Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection , 2018, Clinical Cancer Research.

[30]  T. Tsuzuki,et al.  Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate , 2018, International Journal of Clinical Oncology.

[31]  R. Mathijssen,et al.  Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model , 2017, EBioMedicine.

[32]  K. Akakura,et al.  Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen‐Deprivation Therapy , 2017, Clinical genitourinary cancer.

[33]  A. Ravaud,et al.  Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. , 2017, European urology.

[34]  T. H. van der Kwast,et al.  Intraductal Carcinoma of the Prostate: Anonymous to Ominous. , 2017, European urology.

[35]  D. Murphy,et al.  Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. , 2017, European urology.

[36]  M. Yao,et al.  The Effects of Different Doses and Patterns of Docetaxel Chemotherapy in Japanese Patients with Castration-Resistant Prostate Cancer , 2017, Current Urology.

[37]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.

[38]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[39]  Mahul B Amin,et al.  Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2017, The American journal of surgical pathology.

[40]  Minh N. Do,et al.  Automatic Gleason grading of prostate cancer using quantitative phase imaging and machine learning , 2017, Journal of biomedical optics.

[41]  F. Montorsi,et al.  Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer. , 2017, European urology.

[42]  S. Hayashi,et al.  Estrogen receptor activation by tobacco smoke condensate in hormonal therapy-resistant breast cancer cells , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[43]  S. Aparicio,et al.  The RNA helicase DDX39B and its paralog DDX39A regulate androgen receptor splice variant AR-V7 generation. , 2017, Biochemical and biophysical research communications.

[44]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[45]  Takafumi N. Yamaguchi,et al.  Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories , 2017, Nature Communications.

[46]  T. Tsuzuki,et al.  Incidence of intraductal carcinoma, multifocality and bilateral significant disease in radical prostatectomy specimens from Japan and United States , 2016, Pathology international.

[47]  Sean R. Landman,et al.  Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer , 2016, Nature Communications.

[48]  C. V. von Klot,et al.  Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy , 2016, Oncology letters.

[49]  G. Thalmann,et al.  A Specific Mapping Study Using Fluorescence Sentinel Lymph Node Detection in Patients with Intermediate- and High-risk Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection. , 2016, European urology.

[50]  David S. K. Lu,et al.  Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.

[51]  A. Earnest,et al.  Gleason group concordance between biopsy and radical prostatectomy specimens: A cohort study from Prostate Cancer Outcome Registry – Victoria , 2016, Prostate international.

[52]  Holger Moch,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. , 2016, European urology.

[53]  Y. Oda,et al.  Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7. , 2016, Journal of the National Cancer Institute.

[54]  M. Shiota,et al.  Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone‐sensitive prostate cancer , 2016, International journal of urology : official journal of the Japanese Urological Association.

[55]  R. Shah,et al.  Recent advances in prostate cancer pathology: Gleason grading and beyond , 2016, Pathology international.

[56]  A. Gao,et al.  Lin28 induces resistance to anti‐androgens via promotion of AR splice variant generation , 2016, The Prostate.

[57]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[58]  B. Dai,et al.  Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients , 2016, Asian journal of andrology.

[59]  Jonathan Epstein,et al.  Grading of prostatic adenocarcinoma: current state and prognostic implications , 2016, Diagnostic Pathology.

[60]  R. Stoyanova,et al.  Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity , 2016, Molecular Cancer Therapeutics.

[61]  L. Egevad,et al.  A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. , 2016, European urology.

[62]  Fangting Wu,et al.  Regulation of androgen receptor splice variant AR3 by PCGEM1 , 2016, Oncotarget.

[63]  N. Fujimoto.  Novel agents for castration‐resistant prostate cancer: Early experience and beyond , 2016, International journal of urology : official journal of the Japanese Urological Association.

[64]  Naoto Sassa,et al.  The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation , 2016, Modern Pathology.

[65]  W. Isaacs,et al.  Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization , 2016, The Journal of pathology.

[66]  Xin Qi,et al.  Exploring automatic prostate histopathology image gleason grading via local structure modeling , 2015, 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

[67]  K. Akakura,et al.  Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade. , 2015, The Journal of urology.

[68]  B. Delahunt,et al.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.

[69]  M. Gleave,et al.  AR-v7 protein expression is regulated by protein kinase and phosphatase , 2015, Oncotarget.

[70]  Johan Lindberg,et al.  The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7 , 2015, Scientific Reports.

[71]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[72]  I. Tannock,et al.  Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  Y. Dong,et al.  Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents , 2015, Oncotarget.

[74]  D. Dearnaley,et al.  Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[76]  T. Ahlering,et al.  Surgical margin length and location affect recurrence rates after robotic prostatectomy. , 2015, Urologic oncology.

[77]  Toyonori Tsuzuki,et al.  Intraductal carcinoma of the prostate: A comprehensive and updated review , 2015, International journal of urology : official journal of the Japanese Urological Association.

[78]  R. Shah,et al.  Utility of PTEN and ERG Immunostaining for Distinguishing High-grade PIN From Intraductal Carcinoma of the Prostate on Needle Biopsy , 2015, The American journal of surgical pathology.

[79]  Jiyan Liu,et al.  Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer? , 2015, The Prostate.

[80]  Gary S Collins,et al.  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration , 2015, Annals of Internal Medicine.

[81]  G. Warren,et al.  The biologic effects of cigarette smoke on cancer cells , 2014, Cancer.

[82]  M. Mollenhauer,et al.  Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study. , 2014, European urology.

[83]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[84]  Jun Luo,et al.  Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone , 2014, Hormones and Cancer.

[85]  Shihua Sun,et al.  Mechanisms of the androgen receptor splicing in prostate cancer cells , 2014, Oncogene.

[86]  T. H. van der Kwast,et al.  Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. , 2014, European journal of cancer.

[87]  T. Tsuzuki,et al.  Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens , 2014, The Prostate.

[88]  J. Maroto,et al.  Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer , 2014, British Journal of Cancer.

[89]  S. Eggener,et al.  Development and multi‐institutional validation of an upgrading risk tool for Gleason 6 prostate cancer , 2013, Cancer.

[90]  Michael D. Nyquist,et al.  TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer , 2013, Proceedings of the National Academy of Sciences.

[91]  C. Fiori,et al.  Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. , 2013, Clinical genitourinary cancer.

[92]  K. Harada,et al.  Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. , 2013, Urologic oncology.

[93]  T. H. van der Kwast,et al.  Intraductal carcinoma of the prostate: Precursor or aggressive phenotype of prostate cancer? , 2013, The Prostate.

[94]  Adam T. Szafran,et al.  The activity of the androgen receptor variant AR‐V7 is regulated by FOXO1 in a PTEN‐PI3K‐AKT‐dependent way , 2013, The Prostate.

[95]  A. Ravaud,et al.  Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[96]  S. Taneja,et al.  Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The Journal of urology.

[97]  Seiji Naito,et al.  Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer. , 2012, Endocrine-related cancer.

[98]  L. Klotz,et al.  Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care? , 2012, Current oncology.

[99]  Y. Kubota,et al.  Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel , 2012, PloS one.

[100]  J. Hicks,et al.  Cytoplasmic PTEN Protein Loss Distinguishes Intraductal Carcinoma of the Prostate from High Grade Prostatic Intraepithelial Neoplasia , 2012, Modern Pathology.

[101]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[102]  A. Young,et al.  Frequency and determinants of disagreement and error in gleason scores: A population‐based study of prostate cancer , 2012, The Prostate.

[103]  K. Sotlar,et al.  Prospective assessment of histological serial sectioning of pelvic lymph nodes in prostate cancer: a cost‐benefit analysis , 2012, BJU international.

[104]  C. Fellbaum,et al.  Improving the Reproducibility of the Gleason Scores in Small Foci of Prostate Cancer - Suggestion of Diagnostic Criteria for Glandular Fusion , 2012, Pathology & Oncology Research.

[105]  T. H. van der Kwast,et al.  Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. , 2012, European journal of cancer.

[106]  A. Abdollahi,et al.  Inter/intra-observer reproducibility of Gleason scoring in prostate adenocarcinoma in Iranian pathologists. , 2012, Urology journal.

[107]  W. Berry,et al.  Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. , 2012, European urology.

[108]  R. Vessella,et al.  AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression , 2011, Oncogene.

[109]  Seiji Naito,et al.  Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer. , 2011, Free radical biology & medicine.

[110]  T. Uchiumi,et al.  Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells. , 2011, Free radical biology & medicine.

[111]  G. Sonpavde,et al.  Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[113]  K. Badani,et al.  Gleason score concordance on biopsy‐confirmed prostate cancer: is pathological re‐evaluation necessary prior to radical prostatectomy? , 2011, BJU international.

[114]  S. Verma,et al.  Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. , 2011, AJR. American journal of roentgenology.

[115]  R. Moorin,et al.  A post‐radical‐prostatectomy nomogram incorporating new pathological variables and interaction terms for improved prognosis , 2011, BJU international.

[116]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[117]  J. Epstein,et al.  Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. , 2010, The Journal of urology.

[118]  L. True,et al.  Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer. , 2010, American journal of clinical pathology.

[119]  A. Renshaw,et al.  Protocol for the examination of specimens from patients with carcinoma of the prostate gland. , 2009, Archives of pathology & laboratory medicine.

[120]  E. Giovannucci,et al.  Smoking and aggressive prostate cancer: a review of the epidemiologic evidence , 2009, Cancer Causes & Control.

[121]  Pierre I Karakiewicz,et al.  Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. , 2009, The Journal of urology.

[122]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  R. Engers.  Reproducibility and reliability of tumor grading in urological neoplasms , 2007, World Journal of Urology.

[124]  J. Staffurth,et al.  Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. , 2007, The Lancet. Oncology.

[125]  H. Miyake,et al.  Quantitative Detection of Micrometastases in Pelvic Lymph Nodes in Patients with Clinically Localized Prostate Cancer by Real-time Reverse Transcriptase-PCR , 2007, Clinical Cancer Research.

[126]  Andrea Salonia,et al.  Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. , 2006, European urology.

[127]  F. Montorsi,et al.  Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer , 2006, BJU international.

[128]  P. Scardino,et al.  The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. , 2006, The Journal of urology.

[129]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[130]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[131]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[132]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[133]  M. Resnick,et al.  Association of tobacco use with hormone refractory disease and survival of patients with prostate cancer. , 2004, The Journal of urology.

[134]  M. Kattan,et al.  Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. , 2003, Cancer research.

[135]  C. King,et al.  Prostate biopsy grading errors: A sampling problem? , 2000, International journal of cancer.

[136]  M. Resnick,et al.  Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. , 2000, Urology.

[137]  G. Miller,et al.  Errors in histological grading by prostatic needle biopsy specimens: frequency and predisposing factors , 2000, The Journal of pathology.

[138]  J. McNeal,et al.  Distinction between intraductal carcinoma of the prostate (IDC‐P), high‐grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression , 2000, The Prostate.

[139]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[140]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[141]  P. Scardino,et al.  Patterns of high-grade prostatic intraepithelial neoplasia associated with clinically aggressive prostate cancer. , 1998, Human pathology.

[142]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[143]  M. Rubin,et al.  Cribriform carcinoma of the prostate and cribriform prostatic intraepithelial neoplasia: incidence and clinical implications. , 1998, The American journal of surgical pathology.

[144]  C. Roehrborn,et al.  Gleason Scores from Prostate Biopsies Obtained with 18-Gauge Biopsy Needles Poorly Predict Gleason Scores of Radical Prostatectomy Specimens , 1998, European Urology.

[145]  J. Concato,et al.  A simulation study of the number of events per variable in logistic regression analysis. , 1996, Journal of clinical epidemiology.

[146]  J. McNeal,et al.  Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. , 1996, The American journal of surgical pathology.

[147]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[148]  Mary M. Galloway,et al.  Texture analysis using gray level run lengths , 1974 .

[149]  Robert M. Haralick,et al.  Textural Features for Image Classification , 1973, IEEE Trans. Syst. Man Cybern..

[150]  C. Drake,et al.  Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. , 2018, The Lancet. Oncology.

[151]  T. Tsuzuki,et al.  Prognostic parameter for high risk prostate cancer patients at initial presentation , 2018, The Prostate.

[152]  K. Akakura,et al.  Duration of androgen deprivation therapy and nadir of testosterone at 20 ng / dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy , 2018 .

[153]  Adam T. Szafran,et al.  High‐Content Screening Identifies Src Family Kinases as Potential Regulators of AR‐V7 Expression and Androgen‐Independent Cell Growth , 2017, The Prostate.

[154]  F. Speizer,et al.  Smoking and Mortality - Beyond Established Causes. , 2016, The New England journal of medicine.

[155]  El Naqa,et al.  A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities , 2015 .

[156]  B. Miles,et al.  Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions. , 2014, International journal of clinical and experimental pathology.

[157]  A. D'Amico,et al.  Prostate cancer, version 1.2014. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[158]  Jennifer L. Beebe-Dimmer,et al.  Prognostic Gleason grade grouping : data based on the modified Gleason scoring system , 2013 .

[159]  T. Uchiumi,et al.  Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression , 2010, Oncogene.

[160]  Bernard Fertil,et al.  Texture indexes and gray level size zone matrix. Application to cell nuclei classification , 2009 .

[161]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[162]  Lars Egevad,et al.  Current practice of Gleason grading among genitourinary pathologists. , 2005, Human pathology.

[163]  Shigeo Abe DrEng.  Pattern Classification , 2001, Springer London.

[164]  J. Epstein,et al.  Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. , 2001, Human pathology.

[165]  Anil K. Jain,et al.  Statistical Pattern Recognition: A Review , 2000, IEEE Trans. Pattern Anal. Mach. Intell..

[166]  David G. Stork,et al.  Pattern Classification (2nd ed.) , 1999 .

[167]  Robert King,et al.  Textural features corresponding to textural properties , 1989, IEEE Trans. Syst. Man Cybern..

[168]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[169]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[170]  S. Egawa,et al.  No survival benefit found after extended treatment with docetaxel for patients with castration‐resistant prostate cancer , 2019, The Prostate.

[171]  E. Scarpi,et al.  The Prostate , 2019 .